EyePoint Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. FORM 10-K SUMMARY
Not applicable.
SIGNAT URES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| EYEPOINT PHARMACEUTICALS, INC. | ||
| By: | /s/ Jay S. Duker | |
| Jay S. Duker, M.D. | ||
| President and Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| Date: March 8, 2024 | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /S/ GÖRAN ANDO | Chair of the Board of Directors | March 8, 2024 |
| Göran Ando, M.D. | ||
| /S/ NANCY LURKER | Executive Vice Chair of the Board of Directors | March 8, 2024 |
| Nancy Lurker | ||
| /S/ JAY S. DUKER | President, Chief Executive Officer and Director | March 8, 2024 |
| Jay S. Duker, M.D. | (Principal Executive Officer) | |
| /S/ GEORGE O. ELSTON | Executive Vice President and Chief Financial Officer | March 8, 2024 |
| George O. Elston | (Principal Financial Officer and Principal Accounting Officer) | |
| /S/ WENDY DICICCO | Director | March 8, 2024 |
| Wendy DiCicco | ||
| /S/ YE LIU | Director | March 8, 2024 |
| Ye Liu | ||
| /S/ JOHN LANDIS | Director | March 8, 2024 |
| John Landis | ||
| /S/ DAVID R. GUYER | Director | March 8, 2024 |
| David R. Guyer, M.D. | ||
| /S/ ANTHONY P. ADAMIS | Director | March 8, 2024 |
| Anthony P. Adamis, M.D. | ||
| /S/ KAREN ZADEREJ | Director | March 8, 2024 |
| Karen Zaderej | ||
| /S/ STUART DUTY | Director | March 8, 2024 |
| Stuart Duty | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Consolidated Financial Statements: | |
|---|---|
| Report of Independent Registered Public Accounting Firm on the Financial Statements (PCAOB ID No. 34) | F-2 |
| Consolidated Balance Sheets | F-4 |
| Consolidated Statements of Comprehensive Loss | F-5 |
| Consolidated Statements of Stockholders’ Equity | F-6 |
| Consolidated Statements of Cash Flows | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.